{"cluster": 36, "subcluster": 52, "abstract_summ": "The mortality related to severe acute respiratory distress syndrome (ARDS) and multi-organ failure in COVID-19 patients has been suggested to be connected with cytokine storm syndrome (CSS), an excessive immune response that severely damages healthy lung tissue.Observational data thought to support IL-6 inhibition include elevated circulating IL-6 levels in COVID-19 patients and association between elevated IL-6 and poor clinical outcomes.The use of drugs that inhibit IL-6 biological activity has been proposed as a treatment for patients with Coronavirus Disease 2019 (COVID-19).Excessive immune responses trigger life-threatening cytokine release syndrome (CRS) which can result in overproduction of pro-inflammatory cytokines including tumor necrosis factor alpha (TNF\u03b1), interleukin-6 (IL-6), and IL-1\u03b2 with different pro-inflammatory roles.Drawing on extensive experience administering these and other immune-modulating therapies, the Society for Immunotherapy of Cancer offers this perspective on potential alternatives to anti-IL-6 that may also warrant consideration for management of the systemic inflammatory response and pulmonary compromise that can be seen in patients with severe COVID-19.Interleukin-6 (IL-6) is a pleiotropic cytokine with effects in immune regulation, inflammation, and infection.", "title_summ": "Blocking of the CD80/86 axis as a therapeutic approach to prevent progression to more severe forms of COVID-19Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?Cytochrome P450-mediated drug interactions in COVID-19 patients: current findings and possible mechanismsThe Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory responseRethinking interleukin-6 blockade for treatment of COVID-19N-Acetylcysteine: a potential therapeutic agent for SARS-CoV-2Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-ReviewDiacerein: a potential multi-target therapeutic drug for COVID-19", "title_abstract_phrases": "The mortality related to severe acute respiratory distress syndrome (ARDS) and multi-organ failure in COVID-19 patients has been suggested to be connected with cytokine storm syndrome (CSS), an excessive immune response that severely damages healthy lung tissue.Observational data thought to support IL-6 inhibition include elevated circulating IL-6 levels in COVID-19 patients and association between elevated IL-6 and poor clinical outcomes.Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?One of the primary reasons for high mortality in the advanced stage coronavirus disease-2019 (COVID-19) patients is the uncontrolled inflammation in the lungs leading to acute respiratory distress syndrome (ARDS).The use of drugs that inhibit IL-6 biological activity has been proposed as a treatment for patients with Coronavirus Disease 2019 (COVID-19).We hypothesize that COVID-19 patients are potentially vulnerable to a significant disease-drug interaction, and therefore, suitable dosing guidelines with therapeutic drug monitoring should be implemented to assure optimal clinical outcomes."}